1. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose
- Author
-
Doan Trang Nguyen, Alexander Podreka, Kathryn Szymura, Benjamin Harris, Vincent Caillet, Thomas Eade, Ricky O'Brien, Dasantha Jayamanne, Georgios I. Angelis, Nicholas Hardcastle, Per Rugaard Poulsen, Meegan Shepherd, Jeremy T. Booth, Carol Haddad, Paul J. Keall, and Adam Briggs
- Subjects
Lung Neoplasms ,0299 Other Physical Sciences, 1112 Oncology and Carcinogenesis ,medicine.medical_treatment ,Normal tissue ,Radiosurgery ,Tracking (particle physics) ,SABR volatility model ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Planned Dose ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Oncology & Carcinogenesis ,Stage (cooking) ,Lung ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Radiotherapy Dosage ,Hematology ,Lung Neoplasms/radiotherapy ,Target dose ,Radiation therapy ,Adaptive radiotherapy ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Carcinoma, Non-Small-Cell Lung/diagnostic imaging ,MLC tracking ,Radiotherapy, Intensity-Modulated ,Lung SABR ,business ,Nuclear medicine - Abstract
Background and purposeThe purpose of this work is to present the clinical experience from the first-in-human trial of real-time tumor targeting via MLC tracking for stereotactic ablative body radiotherapy (SABR) of lung lesions.Methods and materialsSeventeen patients with stage 1 non-small cell lung cancer (NSCLC) or lung metastases were included in a study of electromagnetic transponder-guided MLC tracking for SABR (NCT02514512). Patients had electromagnetic transponders inserted near the tumor. An MLC tracking SABR plan was generated with planning target volume (PTV) expanded 5 mm from the end-exhale gross tumor volume (GTV). A clinically approved comparator plan was generated with PTV expanded 5 mm from a 4DCT-derived internal target volume (ITV). Treatment was delivered using a standard linear accelerator to continuously adapt the MLC based on transponder motion. Treated volumes and reconstructed delivered dose were compared between MLC tracking and comparator ITV-based treatment.ResultsAll seventeen patients were successfully treated with MLC tracking (70 successful fractions). MLC tracking treatment delivery time averaged 8 minutes. The time from the start of CBCT to the end of treatment averaged 22 minutes. The MLC tracking PTV for 16/17 patients was smaller than the ITV-based PTV (range -1.6% to 44% reduction, or -0.6 to 18 cc). Reductions in mean lung dose (27 cGy) and V20Gy (50 cc) were statistically significant (p ConclusionThe first treatments with lung MLC tracking have been successfully performed in seventeen SABR patients. MLC tracking for lung SABR is feasible, efficient and delivers high-precision target dose and lower normal tissue dose.
- Published
- 2021
- Full Text
- View/download PDF